KADCYLA for HER2+ metastatic breast cancer

Is KADCYLA right for me? Learn about the potential benefits and risks.

KADCYLA is a prescription medicine used to treat HER2+ breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin^®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.

Talk to your healthcare team about the potential benefits and risks of KADCYLA.

KADCYLA was studied in people with HER2+ metastatic breast cancer

Because everyone is different, no one can say for sure if KADCYLA will work for you, or for how long it will keep working. 

• KADCYLA has been studied in people with HER2+ metastatic breast cancer. These people had already received Herceptin and a taxane (chemotherapy)
• In this study, people took either KADCYLA or a combination of Tykerb^® (lapatinib)* and Xeloda^® (capecitabine)

KADCYLA helped these people live longer

• In this clinical study, people who took KADCYLA lived nearly 6 months longer (30.9 months), on average, than people who took the combination of Tykerb and Xeloda (25.1 months)

KADCYLA made cancer stop growing and spreading for a longer time

• In a clinical study, people who took KADCYLA lived without their cancer growing and spreading for longer (9.6 months), on average, than people who took the combination of Tykerb and Xeloda (6.4 months)
  

Side effects that may occur with KADCYLA

KADCYLA can cause serious side effects including severe liver problems and heart problems. Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects.

Other possible serious side effects of KADCYLA include:

• lung problems
• infusion-related reactions
• serious bleeding
• low platelet count
• nerve damage
• and skin reactions around the infusion site.

See additional information on these side effects below or talk to your doctor.

Hair loss was not common in either study group

• Less than 6% of people who took KADCYLA or lapatinib and capecitabine lost their hair (3.9% in the KADCYLA arm and 5.1% in the lapatinib and capecitabine arm)
  

*Tykerb is a registered trademark of GlaxoSmithKline.